Navigation Links
Anadys Retains Lazard as Strategic Advisor
Date:5/26/2010

-naive genotype 1 patients, treatment with ANA598 for three days led to median end-of-treatment declines in viral load ranging from 2.4 to 2.9 log10 in three separate dose groups.  No patient at any dose level in the monotherapy study showed evidence of viral breakthrough while on ANA598, and there were no serious adverse events.  Those patients from the monotherapy study who subsequently received pegylated interferon and ribavirin all exhibited further viral load decline, demonstrating that viral variants revealed by brief treatment with ANA598 remain susceptible to current SOC, consistent with prior in vitro results.

Anadys has completed two long-term chronic toxicology studies of ANA598 (26 weeks duration in rats and 39 weeks duration in monkeys).  The No Observed Adverse Effect Level, or NOAEL, is 1000 mg/kg, the highest dose tested, in both the rat and monkey.  The completed toxicology studies support the ongoing Phase II clinical study as well as future clinical studies of longer duration.

Anadys has presented in vitro data supporting the use of ANA598 in combination with interferon-alpha as well as with other anti-HCV agents currently in development that act through diverse mechanisms.  In particular, data has shown that ANA598 is synergistic in vitro with interferon-alpha as well as representative HCV protease and polymerase inhibitors.  In vitro combination treatment at clinically relevant concentrations of interferon-alpha and ANA598 results in clearance of HCV RNA from cells rather than selection of resistant isolates.  Furthermore, ANA598 retains full activity in vitro against mutations conferring resistance to protease inhibitors, nucleoside polymerase inhibitors and non-nucleoside polymerase inhibitors that act at binding sites distinct from that of ANA598, while protease and nucleoside polymerase inhibitors retain full
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anadys Pharmaceuticals to Present at the ROTH OC Growth Stock Conference
2. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
3. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
4. Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference
5. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
6. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
8. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
9. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
10. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
11. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Nov. 26, 2014 Lexicon Pharmaceuticals, Inc. ... completion of previously announced concurrent financing transactions resulting ... and estimated offering expenses, Lexicon anticipates net proceeds ... transactions consisted of: , a public ... to a registration statement that has been declared ...
(Date:11/26/2014)... 2014 Investor-Edge has initiated coverage on ... Horizon Pharma PLC (NASDAQ: HZNP ), Endocyte Inc. ... JNJ ), and Theravance Inc. (NASDAQ: THRX ... at: http://investor-edge.com/register . On Tuesday, November 25, ... Dow Jones Industrial Average edged 0.02% lower, to finish the ...
(Date:11/26/2014)... -- Zynerba Pharmaceuticals , Inc., a specialty pharmaceutical ... cannabinoid treatments, today announced that the company will present ... The conference will be held December 2 to 3, ... York . Zynerba,s Chairman and CEO, Armando ... December 2. To listen to a webcast ...
Breaking Medicine Technology:Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2
... bioMerieux, a world leader in the field of in ... that most critical care nurses are unaware of a simple ... The survey, conducted at the 2010 American Association of Critical ... of nurses expressed the need for new tools to battle ...
... 21, 2010 INVO Bioscience, Inc. (OTC Bulletin Board: ... on treatment options for patients diagnosed with infertility, today ... Bolivia.  The initial order of INVOcell devices was purchased ... Under the direction of clinic director Dr. Joaquin Lopez ...
Cached Medicine Technology:Critical Care Nurses Do Not Have Access to Tools They Need to Treat Sepsis 2Critical Care Nurses Do Not Have Access to Tools They Need to Treat Sepsis 3INVO Bioscience Announces First Shipments of INVOcell Into Bolivia 2INVO Bioscience Announces First Shipments of INVOcell Into Bolivia 3
(Date:11/28/2014)... Pittsburgh, PA (PRWEB) November 28, 2014 An ... individuals have day to day. "I got this idea while ... walk to the bathroom," he said. , The Bed Buddy ... person to go to the bathroom. It eliminates the need ... well as promotes comfort and dignity. Easy to use and ...
(Date:11/28/2014)... 2014 ARTAS robotic hair transplant surgical ... time. PAI Medical Group hair transplant surgeons Chris Pawlinga, ... robotic hair transplant procedure in the Brentwood office on ... first in Tennessee and one of only three medical ... ARTAS robotic hair transplantation. Patients benefit from this minimally ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 Based in ... organization focused on delivering exemplary solutions to the income ... ancillary benefits. In an effort to extend its reach ... and asset protection, Secura Consultants has brought aboard financial ... , “I am a big believer in specialization. When ...
(Date:11/28/2014)... TheBeautyPlace.com does it ... offering savings in abundance this retail season. , ... and cosmetic products such as SkinMedica, Neocutis, Glo ... competitive discounts on already reduced prices. At TheBeautyPlace.com ... giving customers savings year round. , TheBeautyPlace.com's Black ...
(Date:11/27/2014)... Albany, NY (PRWEB) November 28, 2014 ... industry is implant dentistry. The market for implant ... as supporting tools/instruments. The global market for dental ... and dental equipments. The dental equipment segment is ... with table of contents at: http://www.researchmoz.us/global-dental-market-report-2014-edition-report.html ...
Breaking Medicine News(10 mins):Health News:First in Tennessee - PAI Medical Group Announces ARTAS - The World’s Most Advanced Medical Robot Used for Hair Transplant Surgery 2Health News:Matt Lee, CLU, ChFC Joins Secura Consultants as New Brokerage Consultant 2Health News:TheBeautyPlace.com Announces Double Savings 2Health News:Dental Market Research Report 2014 - Global Industry Size, Share, Trends, Growth, Retail Sales Value and Forecast by Researchmoz.us 2Health News:Dental Market Research Report 2014 - Global Industry Size, Share, Trends, Growth, Retail Sales Value and Forecast by Researchmoz.us 3
... A device consisting of a giant rubber tube may hold ... sea waves. , Invented in the UK, the ,Anaconda, is ... it would be cheap to manufacture and maintain, enabling it ... of wave energy converter. Cost has been a key barrier ...
... BEACH, Va., July 3 AMERIGROUP,Corporation (NYSE: AGP ... renewed its contract with the State of Tennessee,through June ... for the period April 1, 2008,through June 30, 2008, ... July 1,2008 through June 30, 2009. Expenditures on home ...
... July 3 Mylan Inc. (NYSE: MYL ... has,received tentative approval from the U.S. Food and ... (ANDA) for Linezolid,Tablets, 600 mg., Linezolid Tablets, ... Upjohn,s Zyvox(R) Tablets, which had U.S. sales of ...
... Rigel Pharmaceuticals,Inc. (Nasdaq: RIGL ) today announced that ... will present a company overview,at the Fourth Annual Collins ... a.m. EDT at The Mandarin Oriental Hotel in New ... or the subsequent archived recording,log on to http://www.rigel.com ...
... AND DUSK, DRAIN, SACRAMENTO, Calif., July 2 ... families and friends gathering outdoors, the,Mosquito and Vector ... take precautions against West Nile virus., "Individuals ... to prevent the spread of West Nile Virus ...
... long-term studies to assure medications don,t raise cardiovascular risks, ... to control type 2 diabetes should be subjected to ... the risk of heart problems, U.S. Food and Drug ... experts voted 14-to-2, at the end of a two-day ...
Cached Medicine News:Health News:Rubber 'snake' could help wave power get a bite of the energy market 2Health News:AMERIGROUP Renews Contract with Tennessee 2Health News:Remember West Nile Virus Safety This Fourth of July 2Health News:FDA Panel Calls for More Testing of Diabetes Drugs 2Health News:FDA Panel Calls for More Testing of Diabetes Drugs 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: